FDA Approves Gilead’s New HIV Treatment For Heavily Treated With Multi-Drug Resistant Patients
The FDA has approved Gilead Sciences Inc’s (NASDAQ:GILD) Sunlenca (lenacapavir), in combination with another antiretroviral (s) (ARV), for HIV-1 infection in…
Sunlenca Receives FDA Approval As A First-In-Class, Twice-Yearly Treatment Option For People Living With Multi-Drug Resistant HIV
– Sunlenca is the First and Only Approved Capsid Inhibitor-Based HIV Treatment Option –
– New Drug Application Approval Based on High Rates of Sustained Virologic Suppression in the
Analyzing Gilead Sciences’s Short Interest
Gilead Sciences's (NASDAQ:GILD) short percent of float has fallen 15.15% since its last report. The company recently reported that it has 17.56 million shares sold short, which is 1.4% of all regular shares that are available for trading.
Top M&A Target: Madrigal Pharmaceuticals Could Be Next After Successful NASH Data, Analyst Says
Madrigal Pharmaceuticals Inc (NASDAQ:MDGL) has announced positive topline results from the pivotal Phase 3 MAESTRO-NASH biopsy trial of resmetirom. JMP has…
Why Is Gilead Sciences Stock Sliding Tuesday?
Gilead Sciences Inc (NASDAQ: GILD) shares are trading lower Tuesday after the company reported results from its Phase 2 non-small
Gilead Sciences Announces Anti-TIGIT Domvanalimab-Containing Study Arms Improve Progression-Free Survival Compared To Anti-PD1 Alone In Phase 2 Non-Small Cell Lung Cancer Study
Gilead Sciences, Inc. (NASDAQ:GILD) and Arcus Biosciences, Inc. (NYSE:RCUS) today announced positive results from the fourth interim analysis of the ARC-7 study in patients with first-line, metastatic non-small cell lung
B of A Securities Reinstates Neutral on Gilead Sciences, Announces $85 Price Target
B of A Securities analyst Geoff Meacham reinstates Gilead Sciences (NASDAQ:GILD) with a Neutral and announces $85 price target.
Gilead’s Kites Announced Body of Evidence Grows From ZUMA-7 Study Supporting Initial Treatment With Yescarta CAR T-cell Therapy for Patients With Relapsed or Refractory Large B-cell Lymphoma at ASH 2022
Kite, a Gilead Company (Nasdaq: GILD), today announced findings from two new analyses of the landmark ZUMA-7 trial of Yescarta® (axicabtagene ciloleucel), the largest and longest follow-up of a CAR T-cell therapy versus standard of care (SOC) in patients with relapsed or refractory large B-cell lymphoma (r/r LBCL).
Gilead’s Kite Announced Time to CAR T-cell Therapy May Impact Outcomes for Patients With Relapsed/Refractory Large B-cell Lymphoma in New CIBMTR Analysis at ASH 2022
Kite, a Gilead Company (Nasdaq: GILD), today announced results from one of the largest real-world analyses of patients who received CAR T-cell therapy assessing the impact of time from leukapheresis to infusion ("vein-to-vein" time) for Yescarta® (axicabtagene ciloleucel) in adult patients with relapsed or refractory (R/R